Form 4 for DMAC DiaMedica Therapeutics Inc.
Accepted 2023-04-11 00:00:00 ET · period of report 2023-04-10 · accession 0001235802-23-000040 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-04-11 | 2023-04-10 | DMAC | Wambeke David J. | Chief Business Off | P - Purchase | $1.60 | +468.8K | 468.8K | New | +$750.0K |
| D | 2023-04-11 | 2023-04-10 | DMAC | Wambeke David J. | Chief Business Off | A - Grant | $0.00 | +140.0K | 140.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Voting Common Shares, no par value per share | 2023-04-10 | P | A | 468,750 | $1.60 | 468,750 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2023-04-10 | A | A | 140,000 | $0.00 | 140,000 | D | $1.57 · — to 2033-04-09 | 140,000 Common Shares | (F1) This option vests with respect to 35,000 common shares on April 10, 2024 and with respect to the remaining 75% of the common shares in 12 as nearly equal as possible quarterly installments commencing three months after the one-year anniversary of the grant date. |